Stay updated on Biomarker Response to Immunotherapy in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Biomarker Response to Immunotherapy in NSCLC Clinical Trial page.

Latest updates to the Biomarker Response to Immunotherapy in NSCLC Clinical Trial page
- Check5 days agoChange DetectedThe page shows a revision label updated from v3.6.4 to v3.6.5, indicating a minor platform update to the page. No substantive study content appears to be altered.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoChange DetectedThe page now displays Revision: v3.6.4, updating from Revision: v3.6.3. This indicates a site-wide version update and does not modify study content or results.SummaryDifference0.1%

- Check27 days agoChange DetectedNew update dates were added to the study record indicating the latest post on 2026-07-16 and a QC-approved update on 2026-06-25, while previous timestamps were removed.SummaryDifference0.2%

- Check41 days agoChange DetectedThe page shows Revision: v3.6.3, replacing the prior v3.6.2. This update reflects a new entry version for the ClinicalTrials.gov page rather than changes to the study details.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page revision identifier was updated from v3.6.0 to v3.6.2, indicating a new version of the page content. This update represents a minor administrative change rather than substantive changes to the study details.SummaryDifference0.1%

- Check62 days agoChange DetectedAdded recruitment status note and new user guidance sections (No longer looking for participants, How to Read a Study Record, Common Questions, How to Join a Study) and updated the label to 'Intervention/Treatment'. Removed the old 'Intervention / Treatment' label and updated the revision banner from v3.5.5 to v3.6.0.SummaryDifference0.5%

Stay in the know with updates to Biomarker Response to Immunotherapy in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Biomarker Response to Immunotherapy in NSCLC Clinical Trial page.